Rapid dose-dependent effect of clozapine on a schizophrenic patient's lipid profile

Journal of Psychopharmacology

Volumn 23, Issue 4, 2009, Pages 465-467

  Chiang, Hl ^a   Liu, C C ^a   Hwang, T J ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Clozapine; Dose dependent; Dyslipidaemia; Schizophrenia

Indexed keywords

CHOLESTEROL; CLOZAPINE; EZETIMIBE; FENOFIBRATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; GLUCOSE; HALOPERIDOL; TRIACYLGLYCEROL; TRIFLUOPERAZINE; ZOTEPINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DELUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DYSLIPIDEMIA; HALLUCINATION; HUMAN; IRRITABILITY; LIPID METABOLISM; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TIME FACTORS;

EID: 65649123029     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108091255     Document Type: Article

References (11)

1. American Psychiatric Association (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65: 267 - 272.
2. Baptista T, Kin NM, Beaulieu S, de Baptista EA, (2002) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35: 205 - 219.
3. de Leon J, Henighan V, Stanilla JK, Simpson GM, (1996) Clozapine levels after clozapine discontinuation. J Clin Psychopharmacol 16: 193 - 194.
4. de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruano G, Windemuth A, Diaz FJ, (2007) A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 92: 95 - 102.
5. Eckel RH, Grundy SM, Zimmet PZ, (2005) The metabolic syndrome. Lancet 365: 1415 - 1428.
6. Henderson DC, (2005) Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 66 (Suppl. 6). 11 - 20.
7. Kane JM, Barrett EJ, Casey DE, Correll CU, Gelenberg AJ, Klein S, Newcomer JW, (2004) Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 65: 1447 - 1455.
8. Markham-Abedi C, de Leon J, (2006) Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report. J Clin Psychiatry 67: 1473 - 1474.
9. Newcomer JW, (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68 (Suppl. 4). 8 - 13.
10. Newcomer JW, Sernyak MJ, (2007) Identifying metabolic risks with antipsychotics and monitoring and management strategies. J Clin Psychiatry 68: e17.
11. Wieden PJ, Newcomer JW, (2007) Evidence of switching antipsychotic therapy to improve metabolic disturbances. J Clin Psychiatry 68: e13.